Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.

scientific article published on 24 March 2017

Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/1756-185X.13035
P8608Fatcat IDrelease_fp2kwozh3rf2jfwfgt23cn6bdi
P698PubMed publication ID28337853

P50authorClaire OwenQ85280727
P2093author name stringWendy Stevens
Gene-Siew Ngian
Mandana Nikpour
Susanna Proudman
Catherine Hill
Joanne Sahhar
Janet Roddy
Peter Youssef
Anton Rajadurai
Daniel Boulos
Kathleen Elford
P2860cites workCellular and molecular mechanisms of fibrosisQ24648892
The use of mycophenolate mofetil in transplant recipientsQ33957200
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiativeQ34375158
The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase.Q34457205
Cyclophosphamide versus placebo in scleroderma lung disease.Q34540647
A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phQ35878705
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisQ36171822
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.Q36913821
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung diseaseQ36932914
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysisQ37282448
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trialsQ37301159
Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.Q37310075
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).Q37369608
Evidence-based management of rapidly progressing systemic sclerosisQ37763779
High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trialQ41671784
Improvement in skin thickening in systemic sclerosis associated with improved survivalQ43837375
Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.Q44934375
A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosisQ45889664
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR databaseQ46274957
P433issue4
P921main subjectdiffuse sclerodermaQ18554846
P304page(s)481-488
P577publication date2017-03-24
P1433published inInternational Journal of Rheumatic DiseasesQ15764244
P1476titleLong-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease
P478volume20

Reverse relations

Q91951497Treatment modalities and drug survival in a systemic sclerosis real-life patient cohortcites workP2860

Search more.